Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
about
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Phase Ia study of the indoleam ...... current advanced solid tumors.
@en
Phase Ia study of the indoleam ...... current advanced solid tumors.
@nl
type
label
Phase Ia study of the indoleam ...... current advanced solid tumors.
@en
Phase Ia study of the indoleam ...... current advanced solid tumors.
@nl
prefLabel
Phase Ia study of the indoleam ...... current advanced solid tumors.
@en
Phase Ia study of the indoleam ...... current advanced solid tumors.
@nl
P2093
P2860
P1476
Phase Ia study of the indoleam ...... ecurrent advanced solid tumors
@en
P2093
Andrea Pirzkall
Asha Nayak-Kapoor
Bruce McCall
Charles J Link
Eugene Kennedy
John E Janik
Kari M Morrissey
Laurent Salphati
Lisa Marshall
Mario R Mautino
P2860
P2888
P356
10.1186/S40425-018-0351-9
P577
2018-06-20T00:00:00Z
P6179
1104987361